European Organisation for Research and Treatment of Cancer - EORTC: Central Nervous System Neoplasms trials

The registry lists 23 Central Nervous System Neoplasms studies with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 4Phase 2 13Phase 3 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)Active, not recruitingNCT00626990Phase 3Results posted
• Bevacizumab in Recurrent Grade II and III GliomaCompletedNCT01164189Phase 2
• Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT01019434Phase 2
• Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III MeningiomaStatus unknownNCT00626730Phase 2
• Enzastaurin and Temozolomide in Treating Patients With Primary GliomasStatus unknownNCT00516607Phase 1
• Epothilone ZK-219477 in Treating Patients With Recurrent GlioblastomaCompletedNCT00424060Phase 2
• Radiation Therapy or Temozolomide in Treating Patients With GliomasCompletedNCT00182819Phase 3
• Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00128700Phase 1/2
• Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by SurgeryTerminatedNCT00104936Phase 3
• Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00086879Phase 2
• Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial GliomasStatus unknownNCT00083096Phase 1
• Imatinib Mesylate in Treating Patients With GliomasCompletedNCT00039364Phase 2
• Glufosfamide in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00014300Phase 2
• Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00006353Phase 3
• Nitrocamptothecin in Treating Patients With Glioblastoma MultiformeCompletedNCT00005826Phase 2
• Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00004937Phase 2
• Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During SurgeryCompletedNCT00004015Phase 1
• Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00003939Phase 2
• Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With GliomaCompletedNCT00003916Phase 3
• Temozolomide in Treating Patients With Recurrent Oligodendroglial TumorsCompletedNCT00003731Phase 2
• Temozolomide in Treating Patients With Recurrent Oligodendroglial TumorsCompletedNCT00003304Phase 2
• Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic OligodendrogliomaCompletedNCT00002840Phase 3
• Radiation Therapy in Treating Patients With Brain CancerCompletedNCT00002620Phase 3